Pre-exposure Prophylactic Treatment with Ensitrelvir Inhibited SARS-CoV-2 Infection in Hamster Aerosol Transmission Model

<u>Masaaki Nakashima¹</u>, Haruaki Nobori¹, Takayuki Kuroda¹, Alice Shimba¹, Satoshi Miyagawa¹, Akane Hayashi², Kazumi Matsumoto², Kaoru Baba², Keita Fukao¹ 1 Shionogi & Co., Ltd., Osaka, Japan, 2 Shionogi TechnoAdvance Research, Co., Ltd., Osaka, Japan

Shionogi Pharmaceutical Research Center, Futaba-cho 3-chome, 1-1, 561-0825, Toyonaka, Osaka

E-mail address: masaaki.nakashima@shionogi.co.jp Address: 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan Telephone: +81-70-4029-0023

All authors are employees of Shionogi & Co., Ltd. or Shionogi TechnoAdvance Research, Co., Ltd... Some authors are shareholders of Shionogi & Co.,






Background and Purpose

Although aerosol virus transmission is the major transmission route for SARS-CoV-2 and there remains a need to control SARS-CoV-2 spread with antivirals, prophylactic effect of pre-exposure antiviral treatments to prevent SARS-CoV-2 aerosol transmission remains to be clarified. Here, we administered ensitrelyir to naïve hamsters (contact) prior to exposure of virus aerosol shed by virus-infected hamsters (index) and evaluated the efficacy of the ensitrelvir on SARS-CoV-2 aerosol infection to elucidate the prophylactic effect of ensitrelvir on SARS-CoV-2 aerosol transmission.

Methods


Six Syrian hamsters were intranasally inoculated with hCoV-19/Japan/TY11-927/2021 (delta strain) (index). Six naïve Syrian hamsters (contact) were subcutaneously administered ensitrelyir free form 250 or 750 mg/kg twelve hours before the cohousing based on ensitrelying exposure in human. Index and contact hamsters were co-housed in separated two stainless wire cages to prevent direct viral transmission, and in same container allowing aerosol transmission of SARS-CoV-2 for twelve hours on one day post infection. To evaluate viral titers in lung and nasal lavage fluid (NALF), both samples were collected from index hamsters two days post infection and from contact hamsters four days after cohousing, respectively. To evaluate pathogenesis, body weight changes were monitored until ten days post infection and lung weights were measured ten days post infection.

Figure 1 Hamster SARS-CoV-2 aerosol transmission system [1]




Result

Figure 2 Effect of pre-exposure treatment with ensitrelyir on transmission




vehicle, 250 or 750 mg/kg ensitrelvir


12 hours prior to co-housing



ensitrelvir free form



Ensitrelvir (mg/kg)




Conclusion


▼ : Administration


Pre-exposure treatment with 750 mg/kg ensitrelvir prevented hamsters from aerosol virus infection and suppressed body weight losses and lung weight increases of contact hamsters infected with SARS-CoV-2 via aerosol transmission route. Plasma concentration of ensitrelvir during co-housing was comparable to that of human ten days after initiation of dosing (orally once daily 375 mg on Day 0, 125 mg on Days 1 to 4) [2]. Therefore, the prophylactic effect against SARS-CoV-2 infection could be expected until ten days post first administration in human. These data suggest that prophylactic use of ensitrelyir may help protect at-risk individuals who live or work with SARS-CoV-2-infected patients.


Figure 3 Effect of pre-exposure treatment with ensitrelyir on pathogenesis



- Animal: Male syrian hamster, 6 weeks old, 6 pairs Virus: SARS-CoV-2 delta strain,
- 1×10^3 TCID₅₀/hamster
- Dosing: sc,
- vehicle, 250 or 750 mg/kg ensitrelvir
- 12 hours prior to co-housing







- and (A): Contact co-housed with non-infected index, vehicle O and (B): Contact co-housed with infected index, vehicle
- and (C): Contact co-housed with infected index, 250 mg/kg ensitrelvir
- and (D): Contact co-housed with infected index, 750 mg/kg ensitrelyir

Acknowledgement

SARS-CoV-2 delta strain was a kind gift from National Institute of Infectious Diseases (NIID).

Reference

- [1] Sia SF et al. *Nature*. 2020 Jul;583(7818):834-838.
- [2] Shimizu R et al. Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0063222.